Abstract: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

Abstract: Disclosed herein are methods and compositions for preventing or inhibiting amyloid complex formation of proteins that form pathological aggregates. Examples of these proteins include ?-synuclein, tau protein, TDP-43, transthyretin, uromodulin, islet amyloid polypeptide (IAPP), serum amyloid A (SAA), p53, apolipoprotein E (APOE), APOE-4, prion protein, fibrin, or neurofilament light (NFL), CRP, SUMO, light chain, platelet-derived growth factor receptor (PDGFR), melanoma cell adhesion molecule (MCAM), complement proteins C3 and/or C9, lysozyme, insulin, native haemoglobin (Hb), glycosylated haemoglobin (HbAIC), phenylalanine (Phe), glutamine (Gln), cholesteryl (co-esteryl), cholesterol, neuroserpin, Crystallin AA and/or Crystallin AB, cystatin-C, and myostatin propeptide. These methods and compositions involve antibodies or binding fragments thereof that bind to galectin-3 (Gal3).

Abstract: Provided herein are anti-Gal3 antibodies and methods of use thereof. Such methods include therapies for treating one or more eye diseases including, but not limited to, dry eye disease, glaucoma, age-related macular degeneration, microvascular dysfunction, cataracts, retinal drusen, tear dysfunction, corneal sensitivity, diabetic retinopathy, ocular surface diseases, and other eye diseases.

Abstract: Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.

Abstract: Disclosed herein are methods and compositions for inhibiting, preventing, ameliorating, reducing, or treating cardiovascular diseases, for example, stroke, traumatic brain injury, cerebral amyloid angiopathy, atherosclerosis, myocardial infarction, and/or diseases associated with fibrin activity or dysfunction. These methods and compositions involve antibodies that can bind to Galectin-3 and inhibit, prevent, ameliorate, reduce, or treat the cardiovascular diseases in a patient by reducing inflammation and/or inhibiting oligomerization of proteins associated with pathology such as amyloid beta or fibrin.

Abstract: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

Abstract: Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or glucose transporters. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, insulin resistance, chronic hyperinsulinemia, dysmetabolic syndrome, type A insulin resistance syndrome, type B insulin resistance syndrome, gestational diabetes, acanthosis nigricans, polycystic ovary syndrome (PCOS), obesity, muscle wasting, cardiovascular diseases, cardiac hypertrophy, myocardial ischemia, hypertension, pancreatic cancer associated diabetes (PCDM), rhabdomyosarcoma, or cancers.

Abstract: Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

Abstract: Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.

Abstract: The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).